HSBC Holdings’s Unity Biotechnology UBX Stock Holding History

HSBC Holdings’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,916	Closed	-$117K	–	3197
2019 Q3	$117K	Buy	+1,916	New	+$136K	﹤0.01%	2965

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HSBC Holdings's UBX Position: Q4 2019 in Review

HSBC Holdings sold out of Unity Biotechnology (UBX) in Q4 2019, closing a stake of 1,916 shares — an estimated $117K sold.

HSBC Holdings first reported a position in UBX in Q3 2019 and held it in 1 quarter. The position peaked at $117K in Q3 2019. 79 funds tracked by Wall St. Rank hold UBX as of Q4 2019.

HSBC Holdings reported no remaining Unity Biotechnology position as of Q4 2019 after selling out during the quarter.
HSBC Holdings sold 1,916 Unity Biotechnology shares in Q4 2019, an estimated $117K.
HSBC Holdings first reported a position in Unity Biotechnology in Q3 2019 and held it in 1 quarter.
HSBC Holdings's Unity Biotechnology position peaked at $117K in Q3 2019.
79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2019.

Based on HSBC Holdings's 13F filing for Q4 2019, filed 14 Feb 2020.